Updates in Cancer Cachexia: Clinical Management and Pharmacologic Interventions
Cancers · 27.04.2024 · 16 (9) · 1696
DOI: 10.3390/cancers16091696 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.04.2024. Verfasst von Sudeep Pandey und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology, Oncology and Palliative Care, Virginia Commonwealth University, Richmond, VA 23298, USA. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Despite a better understanding of the mechanisms causing cancer cachexia (CC) and development of promising pharmacologic and supportive care interventions, CC persists as an underdiagnosed and undertreated condition. CC contributes to fatigue, poor quality of life, functional impairment, increases treatment related toxicity, and reduces survival. The core elements of CC such as weight loss and poor appetite should be identified early. Currently, addressing contributing conditions (hypothyroidism, hypogonadism, and adrenal insufficiency), managing nutrition impact symptoms leading to decreased oral intake (nausea, constipation, dysgeusia, stomatitis, mucositis, pain, fatigue, depressed mood, or anxiety), and the addition of pharmacologic agents when appropriate (progesterone analog, corticosteroids, and olanzapine) is recommended. In Japan, the clinical practice has changed based on the availability of Anamorelin, a ghrelin receptor agonist that improved lean body mass, weight, and appetite-related quality of life (QoL) compared to a placebo, in phase III trials. Other promising therapeutic agents currently in trials include Espindolol, a non-selective β blocker and a monoclonal antibody to GDF-15. In the future, a single therapeutic agent or perhaps multiple medications targeting the various mechanisms of CC may prove to be an effective strategy. Ideally, these medications should be incorporated into a multimodal interdisciplinary approach that includes exercise and nutrition.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Hematology, Oncology and Palliative Care, Virginia Commonwealth University, Richmond, VA 23298, USA.
- Department of Medicine, Division of Palliative Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
ORCID-Profile: Sudeep Pandey
Zitieren
APA
Pandey, S., Bradley, L., & Del Fabbro, E. (2024). Updates in Cancer Cachexia: Clinical Management and Pharmacologic Interventions. Cancers, 16(9), 1696. https://doi.org/10.3390/cancers16091696
Vancouver
Pandey S, Bradley L, Del Fabbro E. Updates in Cancer Cachexia: Clinical Management and Pharmacologic Interventions. Cancers. 2024;16(9):1696. doi:10.3390/cancers16091696
BibTeX
@article{Pandey2024,
author = {Pandey, Sudeep and Bradley, Lauren and Del Fabbro, Egidio},
title = {Updates in Cancer Cachexia: Clinical Management and Pharmacologic Interventions},
journal = {Cancers},
year = {2024},
volume = {16},
number = {9},
pages = {1696},
doi = {10.3390/cancers16091696}
}
EUVIMED